{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9BYF1",
      "entity_text" : "ACE2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:10090" ],
      "TissueType" : [ "tissuelist:TS-0568" ],
      "Cellular_component" : [ "go:GO:0043657" ],
      "Organ" : [ "uberon:UBERON:0000479" ]
    }
  },
  "verbose_text" : "To the Editor, In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the letter published by Gerard J O'Mara in the British Medical Journal suggesting that treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) could facilitate coronavirus infection by increasing circulating ACE2 levels, leading to increased viral load and more severe lung injury, has created considerable unease.",
  "reading_complete" : "2020-07-28T11:50:36Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T11:50:28Z",
  "trigger" : "levels",
  "evidence" : [ "ACE2 levels" ],
  "pmc_id" : "7158842",
  "score" : 0
}